Diffuse large B-cell lymphoma trials in China

In China 133 Also abroad 346

133 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
Where
Xiamen
Age
18 years and over
People
53
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT07749365
Phase 2/3Not yet taking people in China
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
Where
Changsha, Chongqing, Harbin, Jinan, Shanghai
Age
18 years to 70 years
People
880
Run by
Dizal Pharmaceuticals
See details and how to joinNCT07712588
Phase 2Taking people
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Where
Tianjin
Age
18 years and over
People
22
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06570447
Phase 1/2Taking people
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Where
Tianjin
Age
18 years and over
People
92
Run by
Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07609862
Phase 2Taking people
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Where
Tianjin
Age
60 years and over
People
58
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07397832
Phase 2Taking people
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Where
Guangzhou
Age
18 years to 80 years
People
60
Run by
Sun Yat-sen University
See details and how to joinNCT07494565
Phase 3Taking people
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Where
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fujian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Ürümqi, Wenzhou, Wuhan, Xiamen, Xi'an, Xi’an, Xuzhou, Zhengzhou
Age
18 years and over
People
240
Run by
Hutchmed
See details and how to joinNCT07409428
Phase 2Not yet taking people in China
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Suzhou
Age
18 years and over
People
96
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07599423
Phase 2Taking people
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
Where
Xuzhou
Age
18 years to 80 years
People
30
Run by
The Affiliated Hospital of Xuzhou Medical University
See details and how to joinNCT07680933
Phase 2Not yet taking people in China
Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma
Where
Changchun
Age
18 years and over
People
66
Run by
Ou Bai, MD/PHD
See details and how to joinNCT07677813
No phaseNot yet taking people in China
Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Where
Hangzhou
Age
18 years and over
People
30
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07669194
Phase 2Taking people
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Where
Shanghai
Age
18 years to 80 years
People
69
Run by
Rong Tao
See details and how to joinNCT07507318
Phase 1/2Taking people
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Where
Tianjin
Age
18 years and over
People
108
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06594640
Phase 2Taking people
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
Where
Nanjing
Age
18 years and over
People
35
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07608978
Phase 1/2Not yet taking people in China
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Where
Guangzhou
Age
18 years and over
People
51
Run by
Sun Yat-sen University
See details and how to joinNCT07601607
Phase 2Taking people
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Where
Wuhan
Age
18 years to 75 years
People
41
Run by
Huazhong University of Science and Technology
See details and how to joinNCT06005870
Phase 2Taking people
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
Where
Wuhan
Age
18 years to 75 years
People
40
Run by
Liling Zhang
See details and how to joinNCT06867536
Phase 1Not yet taking people in China
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Where
Shanghai
Age
18 years and over
People
186
Run by
Chipscreen Biosciences, Ltd.
See details and how to joinNCT07583771
Phase 3Taking people
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
Where
Shanghai
Age
14 years to 75 years
People
640
Run by
Ruijin Hospital
See details and how to joinNCT05018520
Early phase 1Taking people
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Where
Wuhan
Age
18 years to 75 years
People
24
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07548697
Phase 2Taking people
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Where
Beijing
Age
18 years to 75 years
People
43
Run by
Beijing Tongren Hospital
See details and how to joinNCT07523737
Phase 3Not yet taking people in China
A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
Where
Shanghai
Age
18 years to 75 years
People
156
Run by
Ruijin Hospital
See details and how to joinNCT07511114
Phase 2Taking people
R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse
Where
Shanghai, Ürümqi
Age
18 years to 75 years
People
83
Run by
Fudan University
See details and how to joinNCT05257018
Phase 1/2Taking people
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
Where
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi’an, Zhengzhou
Age
18 years and over
People
150
Run by
Dizal Pharmaceuticals
See details and how to joinNCT07059650
Phase 2Taking people
Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
Where
Suzhou
Age
18 years to 70 years
People
35
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07499271